TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04131504

Intervention type: DRUG
Intervention: Infliximab
Description: No standard dosing regimen will be used and the dose will be determined by the treating physician

Intervention type: DRUG
Intervention: Adalimumab
Description: No standard dosing regimen will be used and the dose will be determined by the treating physician
Study: NCT04130360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving
Description: The steps of problem-solving are explained to the participants. Then, they are presented two conflictive situations and they are asked to apply the problem-solving steps to find a solution. Once they finish, they are asked to apply the steps in a conflictive situation they have experience in the last month. In the end, they are reminded of the steps and encouraged to practice them in their daily conflicts.
Study: NCT05162534

Intervention type: OTHER
Intervention: effect of COVID-19 exposure
Description: effect of COVID-19 exposure

Intervention type: OTHER
Intervention: effect of COVID-19 exposure
Description: effect of COVID-19 exposure

Intervention type: OTHER
Intervention: effect of COVID-19 exposure
Description: effect of COVID-19 exposure

Intervention type: OTHER
Intervention: effect of COVID-19 exposure
Description: effect of COVID-19 exposure
Study: NCT02364362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famitinib L + docetaxel
Description: famitinib 15mg qd + docetaxel 60 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famitinib M + docetaxel
Description: famitinib 20mg qd + docetaxel 60 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famitinib H + docetaxel
Description: famitinib 25mg qd + docetaxel 60 mg/m\^2
Study: NCT04654819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental anesthesia simulator usage
Description: Training on dental anesthesia simulator
Study: NCT00969462

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Doxorubicin
Description: measurements of serum Doxorubicin levels
Study: NCT01234662

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPA
Description: Spinal anesthesia and opioids

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSE
Description: CSE and epidural opioids

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSEPCEA
Description: CSE and continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs
Study: NCT01617356

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection of 20% dextrose/ 0.2% lidocaine
Description: Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
Study: NCT02579109

Intervention type: OTHER
Group type: OTHER
Intervention: memory test

Intervention type: OTHER
Group type: OTHER
Intervention: memory test
Study: NCT00799331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5985
Description: Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral suspension.
Study: NCT02789488

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fenugreek seeds extract 500 mg
Description: Furocyst one caps BID
Study: NCT02135315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate
Description: administration of continuous intravenous isosorbide dinitrate to obtain a SBP between 110 and 120 mmHg. After 2 hours from the start of treatment and if the blood pressure goal is not achieved, labetalol is used

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: administration of continuous intravenous isosorbide dinitrate to obtain a SBP between 110 and 120 mmHg. After 2 hours from the start of treatment and if the blood pressure goal is not achieved, labetalol is used
Study: NCT05967845

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cartilage tympanoplasty
Description: cartilage tympanoplasty procedure entails repairing the tympanic membrane perforation by using a piece of cartilage harvested from the patient's auricle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich fibrin augmented tympanoplasty
Description: platelet rich fibrin augmented tympanoplasty entails performing the traditional tympanoplasty using the tempralis fascia as a grafting material. However, platelet rich fibrin clot is obtained from the patient's own blood, and applied to the graft to enhance healing process.
Study: NCT03220815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drilling at low speed
Study: NCT02207712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Standard ranibizumab treatment only
Study: NCT04539912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: angulated screw retained crown
Description: ASC abutment was used in AG;

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cemented crown
Description: prefabricated Ti abutment was used in CG
Study: NCT02501018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLBS12
Description: Intramuscular transfusion of CLBS12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLBS12
Description: Intramuscular transfusion of CLBS12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Standard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids).
Study: NCT02304666

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colonoscopy for biopsies samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy for biopsies samples
Study: NCT01263938

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: For subjects on PI-based HAART therapy: 10mg/day X 2weeks followed by 20mg/day.~For subjects on non PI-based HAART therapy: 20mg/day X 2weeks followed by 40mg/day.
Study: NCT03097991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused Coparenting Consultation
Description: Six 90-minute sessions completed within 10 weeks address importance of coparenting for child development; overcoming challenges to coparenting collaboratively; anger and conflict management and communication skills. Parents develop a coparenting plan to support one another's involvement as parents to the baby. A 90-minute booster session one month after the baby's birth reinforces lessons learned in the 6-session intervention.
Study: NCT03220815

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional drilling at high speed
Study: NCT02418104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-1701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim (Neulasta)
Study: NCT01779245

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Milk-extracted calcium supplement will be used to modulate the calcium content of the milkshakes used.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03150589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB11 (Proposed ranibizumab biosimilar)
Description: SB11 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis (ranibizumab)
Description: Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
Study: NCT03597152

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: WelTract
Description: Supplement commercially available from the sponsor containing powdered extracts from Hibiscus flowers and cranberry fruit, lactoferrin, D-mannose, and vitamins C and D

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert placebo custom manufactured for the sponsor
Study: NCT01214109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole extended release
Description: 0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramipexole extended release
Description: 0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole immediate release
Description: 0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramipexole immediate release
Description: 0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
Study: NCT02451072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules containing mannitol looking identical to LSD per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSD
Description: 100µg per os, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketanserin
Description: 40mg per os, single dose looking identical to LSD per os
Study: NCT04943640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio taping
Description: Kinesio tape was developed by Kenzo Kase in the 1970s. It is an elastic tape, and its adhesive face is sinusoidal wavy. This feature has been shown to increase daily living activities and functions, as it supports the tissue while also allowing movement \[12\]. Kinesio tape lifts the skin and subcutaneous soft tissues of the fascia, which are painful and inflamed regions upon contractions seen in the tissue after tense adhesion to the skin. Therefore, it has been reported to reduce oedema and inflammation by creating more space and providing blood and lymphatic fluid flow.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rigid taping
Description: The tape material used in rigid (athletic) tape application is hard. It is used to position and unite the soft tissue, to protect the tissue from impact and to prevent local swelling.There are studies in the literature supporting the sensorimotor and proprioceptive sensation-enhancing effect of the athletic band, which provides a very good sensory input through the skin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo taping
Description: Placebo taping was applied to the patients in this group, using betafix, an elastic fixation band, as the material. The patient was told that taping would be applied. A straight line betafix was applied to the non-painful scapular inferior level of the spine on the right and left sides of the standing patient.
Study: NCT03973021

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Very small embryonic-like stem cell(VSEL)
Description: Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Very small embryonic-like stem cell(VSEL)
Description: Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Very small embryonic-like stem cell(VSEL)
Description: Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
Study: NCT01502839

Intervention type: OTHER
Intervention: No Intervention
Description: This retrospective data analysis will rely on data obtained from chart review.
Study: NCT02471872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Air Pollution Education
Description: Students are presented with a one-hour interactive session on air pollution.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Air Pollution Education
Description: Students are presented with a one-hour interactive session on vaccines.
Study: NCT01571947

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute Effects of Fats and Carbohydrate
Description: Test meals were served in the form of muffin + milkshake. For high fat meals, 55g of test fat will be incorporated in muffins, whereas 22g of fat for low fat or high carbohydrate test meal. During study day, subjects were to consume the allocated test meal within 10 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute Effects of Fats and Carbohydrate
Description: Test meals were served in the form of muffin + milkshake. For high fat meals, 55g of test fat will be incorporated in muffins, whereas 22g of fat for low fat or high carbohydrate test meal. During study day, subjects were to consume the allocated test meal within 10 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute Effects of Fats and Carbohydrate
Description: Test meals were served in the form of muffin + milkshake. For high fat meals, 55g of test fat will be incorporated in muffins, whereas 22g of fat for low fat or high carbohydrate test meal. During study day, subjects were to consume the allocated test meal within 10 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute Effects of Fats and Carbohydrate
Description: Test meals were served in the form of muffin + milkshake. For high fat meals, 55g of test fat will be incorporated in muffins, whereas 22g of fat for low fat or high carbohydrate test meal. During study day, subjects were to consume the allocated test meal within 10 minutes.
Study: NCT00490906

Intervention type: DRUG
Intervention: Copaxone
Description: 20 mg, subcutaneous injections, taken daily

Intervention type: DRUG
Intervention: Interferon-beta 1a
Description: 30 mcg injected intramuscularly, once weekly

Intervention type: DRUG
Intervention: Interferon-beta 1b
Description: .25 mg/day, taken every other day, subcutaneous injections
Study: NCT01617356

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection of 1 ml of 0.8 SW/0.2% lidocaine
Description: Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine.
Study: NCT03525964

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized treatment of Acute Achilles tendon rupture.
Description: The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the Achilles tendon and the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon and consist of the free tendon and the fascia \[1\]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively. The cut-off at 7% elongation is determined for 75% sensitivity and 65% specificity of elongation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative treatment
Description: Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative treatment
Description: Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
Study: NCT03467360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetazolamide in combination with platinum and etoposide-based radiochemotherapy
Description: Radiation therapy will be combined with platinum and etoposide-based chemotherapy combined with 3-6 tablets per day of acetazolamide during the entire course of therapy (dosage appropriate to the inclusion phase).

Intervention type: DRUG
Group type: OTHER
Intervention: acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC
Description: acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC
Study: NCT00370513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.
Study: NCT00861718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7268
Description: Capsule, Oral, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7268
Description: Capsule, Oral, BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral BID
Study: NCT04093804

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glenosphere size for Reverse Shoulder Arthroplasty
Description: Two randomized study groups will be formed with the consented patients (experimental and control). All patients will undergo reverse shoulder arthroplasty by the Principal Investigator. The experimental group patients will receive a 36mm glenosphere and the control group will receive a 32mm glenosphere. All other procedures during the surgery are identical between groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glenosphere size for Reverse Shoulder Arthroplasty
Description: Two randomized study groups will be formed with the consented patients (experimental and control). All patients will undergo reverse shoulder arthroplasty by the Principal Investigator. The experimental group patients will receive a 36mm glenosphere and the control group will receive a 32mm glenosphere. All other procedures during the surgery are identical between groups.
Study: NCT02472613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Patients will be treated at Renzhong（Du26）, Yintang（EX-HN3）、accupuncture Shangxing（DU23）penetrate to Baihui（DU20）,Sishencong（EX-HN1）; Neiguan（PC6）,Sibai（ST2）,Fengchi（GB20）and Sanyinjiao（SP6）in bilateral;Jianyu（LI15）,Quchi（LI11）,Shousanli（LI10）,Hegu（LI 4）, Fengshi (GB31),Xuehai（SP10） ,Zusanli（ST36）、Taichong（LR 3） of the hemiplegia side. There are another six groups of acupoints in bilateral. The acupuncturist will choose one group acupoints according to patients syndrome:Zhigou (SJ6),Qimen (LR14);Xingjian (LR2),Xiaxi(GB43);Fenglong (ST40),Lianquan(RN23);Tongli (HT5),Xinshu (BL15);Xinshu (BL15),Pishu(BL20);Shenshu (BL23),Taixi (KI3).~The acupoints are inserted at the depth of 20-30mm except Renzhong（Du26）, Sibai（ST2）, Sishencong（EX-HN1）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo was given for 12 consecutive weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham-acupoint acupuncture
Description: Jianliao（SJ14）,Tianquan（PC2）,Xiabai (LU4),Xiaoluo (SJ12),Shouwuli (LI13),Sidu (SJ9),Huizong (SJ7),Wenliu (LI7),Zhouliao (LI12),Quze（PC3）,Kongzui（LI6）,Zhigou（SJ6）,Zhongzhu（SJ3）,Futu（ST32）,Jimen (SP11),Yinshi (ST33),Liangqiu（ST34）,Shangjuxu（ST37）,Xiajuxu（ST39）,Xiyangguan（GB33）,Ligou（LR5）,Pucan (BL61),Jinggu (BL64),Rangu (KI2),Ligou (LR5),Neiting （ST44） of the hemiplegia side.~• The acupoints are inserted at the depth of 20-30mm,except Pucan (BL61),Jinggu (BL64),Rangu (KI2) ,Neiting （ST44）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine was given at a dose of 20 mg/day for12 consecutive weeks.
Study: NCT01030614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: intravenous dexamethasone 8 mgr before laparoscopic cholecystectomy or intravenous placebo before laparoscopic cholecystectomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: intravenous dexamethasone 8 mgr before laparoscopic cholecystectomy or intravenous placebo before laparoscopic cholecystectomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
Study: NCT03046979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
Study: NCT03307031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Volume Group
Description: Performed four weekly session, during 10 weeks with 45 to 55 minutes per session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Volume Group
Description: Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Did not exercise, during 10 weeks.
Study: NCT04748159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone position/ Abdominal position
Description: Standardized positioning of the infant in the prone position respectively abdominal position. Depending on age and size, one or two rolled towels are placed lengthwise under the baby. Both arms are placed cranially in U-position towards the head. Since the position of the head has no significant influence on lung ventilation, the head is placed according to the infant's tolerance.
Study: NCT02567591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: walk (three times per week) and muscle building twice per week with the use of elastic bands. They will include 5 strengthening exercises mobilizing large muscle groups of the lower limbs (abs (if possible for the patient), hamstrings, quadriceps, triceps sural and gluteus maximus).
Study: NCT05560386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: text messaging content to support diabetes prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual workshop
Description: virtual workshop content to support diabetes prevention.
Study: NCT02095444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menstrual blood stem cells
Description: 10\*7 cells/kg, intravenous injection for 4 times during two weeks
Study: NCT00847964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algisyl-LVR
Description: method of left ventricular restoration in patients with dilated cardiomyopathy